Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: A meta-analysis

Endocrine

Volumn 42, Issue 3, 2012, Pages 535-545

  Treglia, Giorgio ^a   Villani, Maria Felicia ^a   Giordano, Alessandro ^a   Rufini, Vittoria ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Fluorodeoxyglucose; Medullary thyroid carcinoma; PET; PET CT

Indexed keywords

CALCITONIN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BLOOD LEVEL; CALCITONIN BLOOD LEVEL; CALCITONIN DOUBLING TIME; CANCER PATIENT; CARCINOEMBRYONIC ANTIGEN BLOOD LEVEL; CHEMICAL PARAMETERS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PATIENT CARE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; THYROID MEDULLARY CARCINOMA; MEDULLARY CARCINOMA; METHODOLOGY; REVIEW; SCINTISCANNING; THYROID TUMOR;

CARCINOMA, MEDULLARY; FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYROID NEOPLASMS;

EID: 84878300686     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9671-6     Document Type: Article

References (42)

1. S.C. Pitt, J.F. Moley, Medullary, anaplastic, and metastatic cancers of the thyroid. Semin. Oncol. 37, 567-579 (2010)
2. American Thyroid Association Guidelines Task Force, R.T. Kloos, C. Eng, D.B. Evans, G.L. Francis, R.F. Gagel, H. Gharib, J.F. Moley, F. Pacini, M.D. Ringel, M. Schlumberger, S.A. Wells Jr, Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19, 565-612 (2009)
3. V. Rufini, G. Treglia, G. Perotti, L. Leccisotti, M.L. Calcagni, D. Rubello, Role of PET in medullary thyroid carcinoma. Minerva Endocrinol. 33, 67-73 (2008)
4. V. Rufini, P. Castaldi, G. Treglia, G. Perotti, M.D. Gross, A. Al-Nahhas, D. Rubello, Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed. Pharmacother. 62, 139-146 (2008)
5. P.F. Whiting, M.E. Weswood, A.W. Rutjes, J.B. Reitsma, P.N. Bossuyt, J. Kleijnen, Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med. Res. Methodol. 6, 9 (2006)
6. A. Oudoux, P.Y. Salaun, C. Bournaud, L. Campion, C. Ansquer, C. Rousseau, S. Bardet, F. Borson-Chazot, J.P. Vuillez, A. Murat, E. Mirallié, J. Barbet, D.M. Goldenberg, J.F. Chatal, F. Kraeber-Bodéré, Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J. Clin. Endocrinol. Metab. 92, 4590-4597 (2007)
7. M. Diehl, J.H. Risse, K. Brandt-Mainz, M. Dietlein, K.H. Bohuslavizki, P. Matheja, H. Lange, J. Bredow, C. Körber, F. Grünwald, Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur. J. Nucl. Med. 28, 1671-1676 (2001)
8. S. Kauhanen, M. Seppänen, J. Ovaska, H. Minn, J. Bergman, P. Korsoff, P. Salmela, J. Saltevo, T. Sane, M. Välimäki, P. Nuutila, The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr. Relat. Cancer 16, 255-265 (2009)
9. R. Czepczyński, J. Kosowicz, K. Ziemnicka, R. Mikołajczak, M. Gryczyńska, J. Sowiński, The role of scintigraphy with the use of 99mTc-HYNIC-TOC in the diagnosis of medullary thyroid carcinoma. Endokrynol. Pol. 57, 431-435 (2006)
10. M. Gotthardt, A. Battmann, H. Höffken, T. Schurrat, H. Pollum, D. Beuter, S. Gratz, M. Béhé, A. Bauhofer, K.J. Klose, T.M. Behr, 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature. Nucl. Med. Commun. 25, 439-443 (2004)
11. A. Boér, S. Szakáll Jr., I. Klein, M. Kásler, B. Vincze, L. Trón, M. Godény, H. Herzog, I. Péter, O. Esik, FDG PET imaging in hereditary thyroid cancer. Eur. J. Surg. Oncol. 29, 922-928 (2003)
12. S. Szakáll Jr, G. Bajzik, I. Repa, T. Miklovicz, G. Dabasi, I. Sinkovics, O. Esik, FDG PET scan of metastases in recurrent medullary carcinoma of the thyroid gland. Orv. Hetil. 143, 1280-1283 (2004)
13. P.S. Conti, J.M. Durski, F. Bacqai, S.T. Grafton, P.A. Singer, Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 9, 797-804 (1999)
14. S. Adams, R.P. Baum, A. Hertel, P.M. Schumm-Dräger, K.H. Usadel, G. Hör, Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. Nucl. Med. Commun. 19, 641-647 (1998)
15. S. Kauhanen, C. Schalin-Jäntti, M. Seppänen, S. Kajander, S. Virtanen, J. Schildt, I. Lisinen, A. Ahonen, I. Heiskanen, M. Väisänen, J. Arola, P. Korsoff, T. Ebeling, T. Sane, H. Minn, M.J. Välimäki, P. Nuutila, Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J. Nucl. Med. 52, 1855-1863 (2011)
16. 18F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma. Nucl. Med. Commun. 32, 1162-1168 (2011)
17. P. Gómez-Camarero, A. Ortiz-de Tena, I. Borrego-Dorado, R.J. Vázquez-Albertino, E. Navarro-González, J.V. Ruiz-Franco-Baux, J.I. Cuenca-Cuenca, Evaluation of efficacy and clinical impact of (18)F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test. Rev. Esp. Med. Nucl. (2011). doi: 10.1016/j.remn.2011.05.010
18. H.W. Jang, J.Y. Choi, J.I. Lee, H.K. Kim, H.W. Shin, J.H. Shin, S.W. Kim, J.H. Chung, Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: comparison with (18)F-FDG PET/CT. Endocr. J. 57, 1045-1054 (2010)
19. E. Skoura, P. Rondogianni, M. Alevizaki, M. Tzanela, S. Tsagarakis, G. Piaditis, G. Tolis, I.E. Datseris, Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer. Nucl. Med. Commun. 31, 567-575 (2010)
20. M.C. Marzola, M.R. Pelizzo, M. Ferdeghini, A. Toniato, A. Massaro, V. Ambrosini, S. Fanti, M.D. Gross, A. Al-Nahhas, D. Rubello, Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur. J. Surg. Oncol. 36, 414-421 (2010)
21. T.V. Bogsrud, D. Karantanis, M.A. Nathan, B.P. Mullan, G.A. Wiseman, J.L. Kasperbauer, C.C. Reading, T. Björo, I.D. Hay, V.J. Lowe, The prognostic value of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. Mol Imaging Biol. 12, 547-553 (2010)
22. B.G. Conry, N.D. Papathanasiou, V. Prakash, I. Kayani, M. Caplin, S. Mahmood, J.B. Bomanji, Comparison of (68)Ga-DOTATATE and (18)F- fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 37, 49-57 (2010)
23. M. Beheshti, S. Pöcher, R. Vali, P. Waldenberger, G. Broinger, M. Nader, S. Kohlfürst, C. Pirich, H. Dralle, W. Langsteger, The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur. Radiol. 19, 1425-1434 (2009)
24. A. Faggiano, F. Grimaldi, L. Pezzullo, M.G. Chiofalo, C. Caracò, N. Mozzillo, G. Angeletti, F. Santeusanio, G. Lombardi, A. Colao, N. Avenia, P. Ferolla, Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer. Endocr. Relat. Cancer 16, 225-231 (2009)
25. K.P. Koopmans, J.W. de Groot, J.T. Plukker, E.G. de Vries, I.P. Kema, W.J. Sluiter, P.L. Jager, T.P. Links, 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J. Nucl. Med. 49, 524-531 (2008)
26. D. Rubello, L. Rampin, C. Nanni, E. Banti, M. Ferdeghini, S. Fanti, A. Al-Nahhas, M.D. Gross, The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur. J. Surg. Oncol. 34, 581-586 (2008)
27. A.L. Giraudet, D. Vanel, S. Leboulleux, A. Aupérin, C. Dromain, L. Chami, N. Ny Tovo, J. Lumbroso, N. Lassau, G. Bonniaud, D. Hartl, J.P. Travagli, E. Baudin, M. Schlumberger, Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J. Clin. Endocrinol. Metab. 92, 4185-4190 (2007)
28. R. Czepczyński, M.G. Parisella, J. Kosowicz, R. Mikołajczak, K. Ziemnicka, M. Gryczyńska, J. Sowiński, A. Signore, Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 34, 1635-1645 (2007)
29. B. Beuthien-Baumann, A. Strumpf, J. Zessin, J. Bredow, J. Kotzerke, Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro- DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 34, 1604-1609 (2007)
30. S.C. Ong, H. Schöder, S.G. Patel, I.M. Tabangay-Lim, I. Doddamane, M. Gönen, A.R. Shaha, R.M. Tuttle, J.P. Shah, S.M. Larson, Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J. Nucl. Med. 48, 501-507 (2007)
31. A. Iagaru, R. Masamed, P.A. Singer, P.S. Conti, Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-d-glucose-PET and PET/CT. Mol. Imaging Biol. 9, 72-77 (2007)
32. M. Gotthardt, M.P. Béhé, D. Beuter, A. Battmann, A. Bauhofer, T. Schurrat, M. Schipper, H. Pollum, W.J. Oyen, T.M. Behr, Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 33, 1273-1279 (2006)
33. J.W. de Groot, T.P. Links, P.L. Jager, T. Kahraman, J.T. Plukker, Impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann. Surg. Oncol. 11, 786-794 (2004)
34. S. Szakáll Jr, O. Esik, G. Bajzik, I. Repa, G. Dabasi, I. Sinkovics, P. Agoston, L. Trón, 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J. Nucl. Med. 43, 66-71 (2002)
35. S. Hoegerle, C. Altehoefer, N. Ghanem, I. Brink, E. Moser, E. Nitzsche, 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur. J. Nucl. Med. 28, 64-71 (2001)
36. K. Brandt-Mainz, S.P. Müller, R. Görges, B. Saller, A. Bockisch, The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur. J. Nucl. Med. 27, 490-496 (2000)
37. S. Adams, R. Baum, T. Rink, P.M. Schumm-Dräger, K.H. Usadel, G. Hör, Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur. J. Nucl. Med. 25, 79-83 (1998)
38. T.J. Musholt, P.B. Musholt, F. Dehdashti, J.F. Moley, Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery 122, 1049-1060 (1997)
39. M. Luster, W. Karges, K. Zeich, S. Pauls, F.A. Verburg, H. Dralle, G. Glatting, A.K. Buck, C. Solbach, B. Neumaier, S.N. Reske, F.M. Mottaghy, Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 20, 527-533 (2010)
40. 68Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC). Endokrynol. Pol. 61, 507-511 (2010)
41. A.J. van der Lely, W.W. de Herder, E.P. Krenning, D.J. Kwekkeboom, Octreoscan radioreceptor imaging. Endocrine 20, 307-311 (2003)
42. G. Treglia, P. Castaldi, G. Rindi, A. Giordano, V. Rufini, Diagnostic performance of gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. (2012). doi: 10.1007/s12020-012-9631-1